Anvisa declines to expand experimental polilaminina use after 9 deaths

Brazil's health regulator Anvisa has publicly explained its refusal to broaden experimental access to polilaminina, citing flaws in study conduct, following nine reported deaths. The agency's stance signals a tightening of oversight on unproven therapies, potentially affecting ongoing clinical trials and patient access. The decision is contested by a researcher, leaving the scientific validity of the drug's safety profile under dispute.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works